骨髓活检在美国国家癌症研究所国家临床试验网络滤泡性淋巴瘤临床试验疗效评估中的相关性
该研究汇总7项试验共580例初治滤泡性淋巴瘤患者数据,发现仅5/580(0.9%)基线骨髓活检阳性且影像学完全缓解后骨髓活检仍阳性,骨髓活检对99%患者疗效评估无影响。影像学完全缓解患者中,骨髓活检确认完全缓解组与未重复活检组无进展生存和总生存无显著差异。作者建议从临床试验要求及诊断指南中去除骨髓活检。
要点
- 仅5/580(0.9%)患者基线骨髓活检阳性且影像学完全缓解后骨髓活检仍阳性,骨髓活检对99%患者疗效评估无影响。
- 影像学完全缓解患者中,骨髓活检确认组与未重复活检组无进展生存和总生存无显著差异。
- 作者建议从临床试验要求中去除骨髓活检,诊断指南中除可能改变管理的情形外也应去除。
核心结论
- 作者结论认为骨髓活检对临床试验中滤泡性淋巴瘤患者疗效评估附加价值小,建议从临床试验要求中去除骨髓活检。
- 作者建议诊断指南中除可能改变管理的情形(包括确认局限期和评估血细胞减少)外也应去除骨髓活检。
研究设计与样本
- 研究汇总了 Alliance for Clinical Trials in Oncology(Alliance)和 SWOG Cancer Research Network(SWOG)7项试验中580例初治滤泡性淋巴瘤患者的数据,入组完成时间为2008年至2016年。
- 敏感性分析纳入了一项 Eastern Cooperative Oncology Group 研究中385例滤泡性淋巴瘤患者。
- 从首次影像学完全缓解起进行 landmark 生存分析,数据来自 Alliance 和 SWOG 的580例患者。
主要发现
- 仅5/580(0.9%)患者基线骨髓活检阳性、影像学完全缓解且后续骨髓活检阳性(P < .0001),骨髓活检对99%患者疗效评估无影响。
- 在 Eastern Cooperative Oncology Group 队列中,5/385(1.3%)患者的骨髓活检影响了疗效评估。
- 影像学完全缓解患者(n = 187)中,骨髓活检阴性确认完全缓解组(n = 47)与未重复骨髓活检组(n = 140)的无进展生存(校正风险比1.10,95%CI 0.62至1.94,log-rank P = .686)和总生存(风险比0.59,95%CI 0.23至1.53,log-rank P = .276)均无显著差异。
临床怎么用
- 作者建议从临床试验要求中去除骨髓活检。
- 作者建议诊断指南中除可能改变管理的情形(包括确认局限期和评估血细胞减少)外也应去除骨髓活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in assessing response or predict progression-free survival (PFS) or overall survival (OS) outcomes in follicular lymphoma (FL) subjects in a large, multicenter, multitrial cohort. METHODS: Data were pooled from seven trials of 580 subjects with previously untreated FL through Alliance for Clinical Trials in Oncology (Alliance) and SWOG Cancer Research Network (SWOG) completing enrollment from 2008 to 2016. RESULTS: Only 5/580 (0.9%) had positive baseline BMB, CR on imaging, and subsequent positive BMB (P < .0001). Therefore, BMB were irrelevant to response in 99% of subjects. A sensitivity analysis of 385 FL subjects treated on an Eastern Cooperative Oncology Group study was included. In the Eastern Cooperative Oncology Group cohort, 5/385 (1.3%) had BMB that affected response assessment. Since some subjects do not undergo confirmatory BMB, we performed a landmark survival analysis from first radiologic CR with data from 580 subjects from Alliance and SWOG. Of subjects with CR on imaging (n = 187), PFS and OS were not significantly different among those with negative BMB to confirm CR (n = 47) versus those without repeat BMB (n = 140; PFS: adjusted hazard ratio, 1.10, 95% CI, 0.62 to 1.94, log-rank P = .686; OS: hazard ratio, 0.59, 95% CI, 0.23 to 1.53, log-rank P = .276). CONCLUSION: We conclude that BMB add little value to response assessment in subjects with FL treated on clinical trials and we recommend eliminating BMB from clinical trial requirements. BMB should also be removed from diagnostic guidelines for FL except in scenarios in which it may change management including confirmation of limited stage and assessment of cytopenias. This would reduce cost, patient discomfort, resource utilization, and potentially remove a barrier to trial enrollment.
引用
- Rutherford SC, Yin J, Pederson L, et al. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2022. PMID: 35787017. doi:10.1200/JCO.21.02301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。